COMBINATION THERAPY WITH SGLT-2 (SODIUM DEPENDENT GLUCOSE CO-TRANSPORTER) INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS

摘要

The present invention is directed to a pharmaceutical composition comprised of one or more SGLT-2 (sodium dependent glucose co-transporter) inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class I obesity, class II obesity, class III obesity, visceral obesity and abdominal obesity, and metabolic syndrome.